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Background: The accuracy of currently available same-day diagnostic tools (smear microscopy and conventional
nucleic acid amplification tests) for pleural tuberculosis (TB) is sub-optimal. Newer technologies may offer improved
detection.
Methods: Smear-microscopy, adenosine deaminase (ADA), interferon gamma (IFN-γ), and Xpert MTB/RIF [using an
unprocessed (1 ml) and centrifuged (~20 ml) sample] test accuracy was evaluated in pleural fluid from 103 consecutive
patients with suspected pleural TB. Culture for M.tuberculosis and/or histopathology (pleural biopsy) served as the
reference standard. Patients were followed prospectively to determine their diagnostic categorisation.
Results: Of 93 evaluable participants, 40 had definite-TB (reference positive), 5 probable-TB (not definite but treated for
TB) and 48 non-TB (culture and histology negative, and not treated for TB). Xpert MTB/RIF sensitivity and specificity
(95% CI) was 22.5% (12.4 - 37.6) and 98% (89.2 - 99.7), respectively, and centrifugation did not improve sensitivity
(23.7%). The Xpert MTB/RIF internal positive control showed no evidence of inhibition. Biomarker specific sensitivity,
specificity, PPV, and NPVs were: ADA (48.85 IU/L; rule-in cut-point) 55.3% (39.8 - 69.9), 95.2% (83.9 - 98.7), 91.4 (73.4 - 95.4),
69.7% (56.7 - 80.1); ADA (30 IU/L; clinically used cut-point) 79% (63.7 - 89), 92.7% (80.6 - 97.5), 91.0 (73.4 - 95.4), 82.7%
(69.3 - 90.1); and IFN-γ (107.7 pg/ml; rule-in cut-point) 92.5% (80.2 - 97.5), 95.9% (86.1 - 98.9), 94.9% (83.2 - 98.6), 93.9%
(83.5 - 97.9), respectively (IFN-γ sensitivity and NPV better than Xpert [p < 0.05] and rule-in ADA [p < 0.05]).
Conclusion: The usefulness of Xpert MTB/RIF to diagnose pleural TB is limited by its poor sensitivity. IFN-γ is an excellent
rule-in test and, compared to ADA, has significantly better sensitivity and rule-out value in a TB-endemic setting.
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Tuberculosis (TB) remains a global health problem, with
an estimated 1.4 million deaths and 8.7 million new
cases reported in 2011 [1]. Pulmonary TB is the most
common form of TB, with extrapulmonary TB (EPTB)
accounting for ~15% of cases, but this estimate increases
to ~50% in high HIV prevalence settings [2]. Pleural TB,* Correspondence: keertan.dheda@uct.ac.za
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unless otherwise stated.a common form of EPTB, remains a common problem
for physicians practising in high, intermediate and low
TB burden settings, particularly where there are large
immigrant populations. The diagnosis of pleural TB is
challenging due to the paucibacillary nature of biological
samples, and the need for diagnostic confirmation using
invasive, expensive, and time consuming procedures
such as blind pleural biopsy, imaging-guided-pleural bi-
opsy, and medical or surgical thoracoscopy [3].
Proxy markers such as adenosine deaminase (ADA),
an enzyme that catalyzes the conversion of adenosine
and deoxyadenosine to inosine and deoxyinosine hasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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inexpensive and rapid, with pooled sensitivity and speci-
ficity estimates of 92% and 90%, respectively, across dif-
ferent prevalence settings depending on the cut-point
used [4]. Interferon gamma (IFN-γ), an inflammatory
cytokine secreted from macrophages and CD4 (+) T cells
in response to M. tuberculosis infection, and that tends
to concentrate in the pleural space, has been shown to
be an alternative biological marker for pleural TB diag-
nosis with pooled sensitivity and specificity estimates of
89% and 97%, respectively [5]. In high TB/HIV burden
settings the performance was shown to be even better:
sensitivity 97% and specificity 100% [6].
More recently the Xpert MTB/RIF assay, a fully auto-
mated quantitative real-time hemi-nested PCR, was in-
troduced into high burden settings and is able to detect
M. tuberculosis within 2 hours and also provide informa-
tion about rifampicin susceptibility [7]. The assay has
been validated using sputum samples and recently en-
dorsed by the WHO as a rapid test for both smear-
positive and smear-negative (paucibacillary) respiratory
samples [8,9]. However, there are limited data about the
Xpert MTB/RIF assay using pleural fluid [10-17] and
thus the usefulness of this assay in the context of pleural
TB remains unclear. Limitations of previously published
work include the relatively small number of patients
with pleural TB (usually quoted as part of a larger series
of patients with EPTB), a paucity of biopsy-proven or
culture positive samples as a gold standard, the lack of
comparative analysis with other commonly used bio-
markers, and a lack of attention to the technical factors
that could impact Xpert MTB/RIF performance, includ-
ing PCR inhibition, level of detection, and correlation
with bacterial load. Furthermore, there are also limited
data from high TB and HIV prevalence settings.
To address these knowledge gaps we prospectively
evaluated the performance of the Xpert MTB/RIF assay,
and other same-day diagnostic biomarkers, using pleural
fluid obtained from patients with suspected pleural TB
from Cape Town in South Africa.Methods
Patient recruitment, characterization and routine
laboratory tests
Consecutive patients with suspected pleural TB, includ-
ing any symptoms including cough, fever, night sweats,
loss of weight, haemoptysis and chest pain, and features
consistent with a pleural effusion on chest x-ray, were
prospectively recruited from Groote Schuur, Somerset
and Victoria Hospitals in Cape Town, South Africa, over
a three year period from October 2009 to September
2012. The University of Cape Town Human Research
Ethics Committee approved the study, and all patientsprovided written informed consent for study participa-
tion and pleural biopsy.
Routine TB diagnostic work up (pleural fluid analysis,
sputum for microscopy and culture, when available, and
lymph node or other organ biopsy) was performed by
the referring physician. Although not routine, a closed
pleural biopsy using an Abrams needle was performed
by a study physician trained in this procedure to im-
prove patient categorization. All biopsies were per-
formed after aspiration of pleural fluid. Patients were
offered voluntary HIV testing. Pleural fluid samples were
collected for routine biochemical and cytological analysis
(protein, albumin, ADA, glucose, cell differential, cy-
tology), concentrated fluorescence smear microscopy,
and liquid culture for M. tuberculosis using the MGIT
960 (Becton Dickinson, Sparks, Maryland) with the
remaining fluid used for Xpert MTB/RIF and IFN-γ ana-
lysis. Pleural biopsy samples were sent for histology and
liquid culture. Adenosine deaminase activity in pleural
fluid was determined by colorimetric technique by the
National Health Laboratory Services, using the user-
defined method on a Roche Cobas Integra (Roche Diag-
nostics Ltd, Switzerland). Pleural fluid ADA levels
greater than 30 U/L, in keeping with local guidelines
and clinical practice, were reported as suggestive of
pleural TB [18,19].
Given the limitations of a single pleural fluid TB cul-
ture for confirming a diagnosis, patients were cate-
gorised as follows: Definite-TB: patients with at least one
positive M. tuberculosis culture by liquid culture (in ei-
ther pleural fluid, biopsy or sputum) and/or caseating
granulomatous inflammation suggestive of TB on histo-
logical examination of pleural biopsy tissue, and with
improvement on anti-TB treatment (all patients in this
category received anti-TB treatment); Probable-TB: pa-
tients not meeting the criteria for definite-TB but with a
clinical-radiological picture suggestive of TB and who
were treated for TB with clinical response (all patients in
this category received anti-TB treatment); Non-TB: pa-
tients for whom no microbiological or histological evi-
dence of M. tuberculosis could be found, and/or for
whom an alternative diagnosis was available. These pa-
tients at presentation and on follow-up did not receive
anti-TB treatment.
All the laboratory staff performing the requested tests,
including Xpert MTB/RIF and IFN-γ measurement, were
blinded to all microbiological and clinical information.
IFN-γ measurement
Interferon gamma (IFN-γ) concentrations were measured
in pleural fluid supernatant in duplicate using the Inter-
Gam Ultrasensitive Rapid Immuno-suspension Assay
(IRISA; Antrum Biotech, Cape Town, South Africa; limit
of detection = 5 to 10 pg/ml). Pleural fluid supernatant
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15 min to remove any unwanted debris.
Xpert MTB/RIF assay
A 1 ml aliquot of raw pleural fluid and a 1 ml aliquot of
concentrated (centrifuged) pleural fluid from each pa-
tient was diluted with 2 ml of the Xpert MTB/RIF sam-
ple buffer. The 1 ml concentrated pleural fluid aliquot
was prepared by centrifugation of a median (IQR) of 20
(10-20) ml pleural fluid at 3000×g for 15 min, with the
supernatant discarded and the pellet made up to 1 ml
with phosphate buffer solution. The pleural fluid and
sample buffer solutions were then mixed vigorously and
incubated at room temperature for 15 min, with further
mixing halfway through the incubation. A 2 ml volume
of the diluted samples was then transferred to an Xpert
MTB/RIF cartridge and run on the GeneXpert (Cepheid,
Dx System Version 4.0c) machine. The limit of detection
was determined in duplicate by spiking 0, 50, 75, 100
and 150 H37Rv CFU to 1 ml aliquots of pleural fluid
from subjects confirmed not to have TB, before dilution
with sample buffer and subsequent Xpert MTB/RIF ana-
lysis. This experiment was repeated twice. Inhibition was
evaluated by comparing the PCR cycle-threshold (CT)
values of the internal positive control (lyophilized Bacillus
atrophaeus subsp. globigii spores) from unconcentrated
and concentrated samples.
Statistical analysis
Categorical variables were compared using the χ2 test
and continuous variables were compared using Student’s
t-test where appropriate, with Mann-Whitney used for
non-parametrically distributed continuous variables.
Correlations were analyzed using the Spearman co-
efficient for non-parametrically distributed variables.
Diagnostic accuracy, including 95% confidence intervals,
was assessed using sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV)
(Open Epi, Version 2.3.1) and area under the receiver
operator curve (AUROC) in definite-TB and non-TB
groups (Graphpad Prism, Version 5.03).
Results
A total of 103 patients with pleural effusion and sus-
pected TB were enrolled. Ten patients were excluded
from the final analysis: three had incomplete clinical
data and seven were on anti-TB treatment for more than
48 hours prior to the samples being taken (see Figure 1
for patient flow and test results available).
Clinical and demographic data
Forty subjects were confirmed to have definite-TB, 48
non-TB and 5 participants probable-TB (not meeting
diagnostic criteria but receiving TB treatment). Thesubjects with non-TB effusions had a spectrum of malig-
nant and non-malignant diagnoses including: lymphoma,
adenocarcinoma, small cell carcinoma, and parapneu-
monic effusion. Of the 65 subjects consenting to HIV
testing, 17% (11) were positive. Clinical and demo-
graphic data are summarized in Table 1.
Performance outcomes of IFN-γ
IFN-γ levels were evaluated in 93 patients (40 definite-
TB, 5 probable-TB and 48 non-TB). Median (IQR) IFN-γ
levels were approximately 100 times higher in definite-TB
compared to non-TB effusions: 131.8 (131.8-162.7) versus
0.57 (0.0-5.71) pg/ml, p < 0.0001 (Figure 2). A receiver op-
erating characteristic (ROC) curve derived rule-in cut
point of 107.7 pg/ml was used to determine the sensitivity
and specificity (95% CI) (Figure 3). Table 2 compares the
diagnostic accuracy of the IFN-γ with other same-day
diagnostics in definite-TB versus non-TB groups. IFN-γ
sensitivity was unaffected by the inclusion of probable-
with definite-TB patients (see Additional file 1: Table S1 in
the online supplementary data), and diagnostic accuracy
was not significantly different in HIV-infected compared
to uninfected patients (see Additional file 1: Table S2 in
the online supplementary data).
Performance outcomes of pleural fluid ADA
Adenosine deaminase levels were measured in 84 pa-
tients. Median (IQR) ADA levels were 5 times higher in
definite-TB compared to non-TB effusions: 51.7 (35.2-
62.1) versus 11.5 (7.1-18.8) U/L, p < 0.0001. Using a clin-
ical cut point of >30 U/L (South African national standard
[18]), the sensitivity (95%CI), specificity, NPV and PPV
were 79.0% (63.7-89.0), 92.7% (80.6-97.5), 82.7% (69.3-
91.0) and 91.0% (73.4-95.4), respectively (Table 2). Rele-
vant values using the rule-in cut-point (at least 95%
specificity) are shown in Table 2. The ROC and scatter
plot of ADA are shown in Figures 2 and 3.
Grouping the probable TB with the definite-TB group
reduced the sensitivity to 74.5% but the specificity
remained unchanged, when using the clinically used cut
point of >30 U/L. A similar trend occurred when using
the rule-in cut point of 48.85 U/L (see Additional file 1:
Table S1 in the online supplementary data). HIV status
had no significant impact on the ADA diagnostic accur-
acy (see Additional file 1: Table S3 in the online supple-
mentary data).
Performance outcome for Xpert MTB/RIF assay including
inhibition and detection threshold
Xpert MTB/RIF was performed on 93 participants.
Xpert MTB/RIF detected 9 out 40 subjects with definite-
TB. The sensitivity (95%CI) and specificity using 1 ml of
unprocessed pleural fluid was 22.5% (12.4, 37.6) and
98.0% (89.2, 99.7) respectively. Xpert MTB/RIF sensitivity
Figure 1 Patient flow and test results available for final diagnoses. $biopsy not performed (n = 1); *no fluid smear requested (n = 15); #liquid
culture not requested, pleural fluid (n = 17) and pleural biopsy (n = 12); §indeterminate liquid culture: contamination (n = 1) and sample rejected
(n = 1); ◊histology not requested (n = 1); □ADA measurements not requested (n = 9); †sample lost during processing (n = 1), ‡indeterminate Xpert
MTB/RIFF result (n = 7).
Meldau et al. BMC Pulmonary Medicine 2014, 14:58 Page 4 of 10
http://www.biomedcentral.com/1471-2466/14/58and specificity did not improve when a concentrated (cen-
trifuged) pleural fluid samples was used (p = 0.90, Table 3).
However, the number of indeterminate results generated
in concentrated compared to unprocessed pleural fluid
samples was higher 7/92 vs. 0/93 (p < 0.05). Table 2 com-
pares the diagnostic accuracy of Xpert MTB/RIF and
other same-day diagnostics. Of note, Xpert MTB/RIF
pleural fluid testing detected one rifampicin-resistant re-
sult that was confirmed by liquid culture to be a true-
positive MDR-TB case.
Spiking raw pleural fluid demonstrated that the Xpert
MTB/RIF assay was able to reliably detect ≥75 CFU per
millilitre of pleural fluid (Figure 4a). No significant dif-
ference was seen between unprocessed and concentrated
pleural fluid internal probe amplifications with median
CT values of (95% CI) of 27.6 (27.5, 28.5) and 27.4 (27.6,
28.9), respectively. The median time-to-positivity (TTP)
(IQR) for pleural fluid and pleural biopsy culture were
28.0 days (23.3-31.1) and 19.0 days (17.7-24.6), respect-
ively (data not shown). No correlation was observedbetween CT values and TTP from pleural fluid liquid
culture, however, there was a correlation (Spearman r =
0.93, p = 0.02) between CT values and the TTP from
pleural biopsy culture.
In contrast to the findings with ADA and IFN-γ, when
subjects were stratified by HIV status, Xpert MTB/RIF
had a higher sensitivity in HIV infected versus unin-
fected persons [50% (21.6-78.5) vs. 9.1% (2.6-27.9), p =
0.031 (see Additional file 1: Table S4 in the online
supplementary data). A similar trend was seen when
comparing pleural fluid and biopsy culture as reference
standard (see Additional file 1: Table S5 in the online
supplementary data).
Xpert MTB/RIF in combination with ADA or IFN-γ
did not significantly improve the diagnostic accuracy
when compared to ADA or IFN-γ alone (Table 2).
Discussion
Given that a reliable same-day diagnostic tool for pleural
TB is lacking, we prospectively evaluated and compared
Table 1 Baseline characteristics of the definite tuberculosis
(TB) and non-TB patients
Definite-TB Non-TB p-value
Patients (n) 40 48
Age (yrs) 39 (29,55) 61 (54,69) <0 · 0001#
Sex
Male 24 (60%) 29 (60.4%)
Female 16 (40%) 19 (39.6%)
Race
White 1 (2.5%) 5 (10 . 4%)
Black 28 (70%) 9 (18.8%) <0.0001*
Mixed 11 (27.5%) 34 (70.8%) <0.0001*
HIV Status
HIV-infected 8 (20%) 1 (2 . 0%) <0.05*
HIV uninfected 22 (55%) 29 (60.4%)
Refused testing 4 (10%) 3 (6.3%)
Unknown 6 (15%) 15 (31.3%)
History of Previous TB
Yes 6 (15%) 5 (10.4%)
No 31 (77 . 5%) 39 (81.3%)
Unknown 3 (7.5%) 4 (8.3%)
BCG Status
Yes 20 (50%) 25 (52.1%)
No 10 (25%) 5 (10.4%)
Unknown 10 (25%) 18 (37.5%)
Current smoker
Yes 7 (17.5%) 18 (37.5%) <0.05*
No 32 (80%) 26 (54.1%) <0.05*
Unknown 1 (2.5%) 4 (8.3%)
Data are presented as median (IQR) or n (%) or yrs (IQR). BCG: bacilli
Calmette-Guerin. #: unpaired t-test; *: Chi-squared test.
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pleural fluid from patients with suspected TB. Our key
findings were (i) Xpert MTB/RIF had poor sensitivity
and this was neither the result of a sub-optimal level of
detection compared to other types of biological samples
nor increased PCR inhibition, (ii) Xpert MTB/RIF sensi-
tivity was not improved by concentrating larger volumes
of pleural fluid, (iii) ADA and IFN-γ are good rule-in
tests for TB pleural effusions but the higher sensitivity of
IFN-γ would be preferable over ADA for rule-in, par-
ticularly in low-burden settings where a high INF-γ level
is unlikely to be due to cancer, (iv) the excellent rapid
rule-out value of IFN-γ, compared to ADA, is of particu-
lar clinical usefulness in high burden settings as it could
be used to prompt a search for an alternative diagnosis
and hence medical or surgical biopsy. The sheer burden
of disease and resource constraints, including lack of
skilled operators, in high burden settings means that aroutine biopsy-based approach cannot be undertaken.
Moreover, the majority of patients suspected with
pleural TB were unable to produce sputum.
The Xpert MTB/RIF assay, which can simultaneously
detect the presence of M. tuberculosis and rifampicin re-
sistance in sputum specimens, has shown great promise
in the rapid diagnosis of TB, with an average sensitivity
and specificity of 90.4% and 98.4%, respectively [8]. It
has also improved the rapid diagnosis of pulmonary TB
(sensitivity of ~68%) in smear-negative patients and re-
cently been endorsed by the Scientific and Technical
Advisory Board of the WHO for use in paucibacillary
samples [9,20]. However, there are hardly any data about
Xpert performance in pleural fluid. Published studies
have generally been performed in low burden settings as
a laboratory exercise reporting yields in samples from
extra-pulmonary sites, and only reported on a handful of
patients with TB pleural effusion [10,12-16]. This may
explain the high sensitivity reported in these studies
(range 58% to 100%) and high specificities (87% to
100%) [10-16]. Recently Friedrich and co-workers in a
selected cohort found that 20 out of 25 patients had
confirmed TB and that Xpert sensitivity was 25% [11].
We have confirmed these findings in a larger unselected
cohort and further interrogated the technical perform-
ance of the assay. The level of detection was ≥75 colony
forming units per ml, and there was no evidence of PCR
inhibition using the internal positive control. Centrifuga-
tion of pleural fluid made little difference. The time to
positivity data (median > 28 days) confirms the low or-
ganism load within the pleural space compared to
pleural tissue. Indeed, there was a trend to shorter time
to positivity in liquid culture from samples that were
culture positive/Xpert positive compared to those that
were culture positive/Xpert negative (data not shown).
Collectively, these data confirm the notion that pleural
TB is a paucibaciliary disease and thus concentration/
centrifugation of at least 20 ml of pleural fluid makes lit-
tle difference to diagnostic yield. Xpert performed better
in HIV-infected individuals, which may reflect a higher
organism load in the pleural fluid [21].
In high burden settings such as South Africa, a high
ADA level is frequently used to guide initiation of anti-
TB therapy [4,5]. In this study, although ADA levels
were 5 times higher in TB patients than in non-TB pa-
tients, using the laboratory accepted cut-point in Cape
Town (30 U/L) roughly 20% of TB patients would have
been missed and 1 in 10 incorrectly started on anti-TB
therapy. Despite the inability of ADA to definitively con-
firm M. tuberculosis, it is a low cost and relatively rapid
(same day) assay and has a high PPV when disease
prevalence is high [22]. In low prevalence settings, how-
ever, PPV is too low to be clinically useful. Indeed, a re-
cent meta-analysis of 63 studies including 2796 pleural TB
Figure 2 Scatter plot of interferon gamma (IFN-γ) and adenosine deaminase (ADA) using pleural fluid from patients with TB and
non-TB pleural effusions. *: p < 0.0001 (Mann-Whitney). See Additional file 1: Table S6 in the online supplementary data for final diagnosis of
non-TB patients with ADA and/or IFN-γ levels above cut points.
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of ADA to be 92% and specificity 90% at a cut-point of
41.9 U/L (median cut-point in the pooled studies, which
each used a different cut-point) [4]. Thus, 1 in 10 patients
would be over diagnosed with TB. The specificity of ADA
may be improved if the proportion of lymphocytes is taken
into account as was recently shown [22]. However, this is
not universally helpful as about ~25% of TB pleural effu-
sions , may be neutrophil predominant [23].
Interferon gamma, similarly, was significantly higher
in TB (100 fold) compared to non-TB patients. Using an
ROC curve-determined cut-point of 107.7 pg/ml, only 3
definite-TB patients were missed. By contrast, Xpert sen-
sitivity, like pleural fluid culture (~40%) [2], was poorFigure 3 Area under the receiver operator characteristic (ROC)
curves for interferon gamma (IFN-γ) and adenosine deaminase
(ADA) were 0.94 and 0.91, respectively.and therefore additional tools are required for optimal
diagnosis when a non-biopsy approach is used. Thus, a
‘one size fits all’ approach with Xpert is inappropriate.
Although closed pleural biopsy has a high diagnostic
yield it is often unavailable in resource-poor settings,
and even when available the large numbers of cases pre-
clude routine biopsy in district general hospitals. In this
study we have confirmed our previous findings, and
those of others, that IFN-γ is both a highly accurate
rule-in and rule-out diagnostic test for pleural TB
[6,24-26], however it must be accepted that the
107.7 pg/ml cut point was generated using the current
cohort and further prospective testing is required to
confirm the high sensitivity and specificity. Although it
can be easily measured by a commercially available
ELISA-kit, it is not routinely performed due to the high
cost and the kits only being available in a 96 well format,
which lead to a considerable wastage of unused wells
[27]. Interestingly, of the only two non-TB patients that
had elevated IFN-γ, one patient had an empyema, which
is known to cause elevated IFN-γ and is a contra-
indication to using the test, and the other patient was
lost to follow-up and thus the true TB status was un-
clear. A previous study from our group demonstrated a
similar accuracy (sensitivity 97% specificity 98%) [6]. An
obvious drawback is the lack of susceptibility data, but
in resource-poor settings culture confirmation with sus-
ceptibility can follow if there is a poor response to treat-
ment. In any event a culture isolate or positive NAAT
would be required to determine susceptibility- the yield
of both are low in pleural TB. It would have been inter-
esting to perform Xpert on the pleural tissue biopsies
but technically this was not feasible due to the limited
Table 2 Per patient diagnostic accuracy of Xpert MTB/RIF, IFN-γ, and ADA for the diagnosis pleural tuberculosis
Assay Definite-TB vs. Non TB
Sensitivity% (95% CI) Specificity% (95% CI) PPV% (95% CI) NPV% (95% CI) +LR (95% CI) -LR (95% CI)
Xpert MTB/RIF 22.5% *#□$£ (12.4, 37.6) 9/40 98% (89.2, 99.7) 47/48 90% (59.6, 98.3) 9/10 60.3% †◊●▪ (49.2, 70.4) 48/78 10.8 (1.43, 81.65) 0.79¢º¤§¿ (0.67, 0.94)
IFN-γ 92.5%*O (80.2, 97.5) 37/40 95.9% (86.1, 98.9) 46/48 94.9% (83.2, 98.6) 37/39 93.9%†∞ (83.5, 97.9) 46/49 22.20 (5.70, 86.46) 0.08¢ð (0.03, 0.23)
ADA (Clinical cut point) 79% Δ#× (63.7, 89) 30/38 92.7% (80.6, 97.5) 38/41 91% (73.4, 95.4) 30/33 82.7% ‡◊ (69.3, 91.0) 38/46 10.79 (3.59, 32.47) 0.23º (0.12, 0.42)
ADA (Rule-in cut point) 55.3% □O×€¥ (39.8, 69.9) 21/38 95.2% (83.9, 98.7) 39/41 91.4% (73.3, 97.6) 21/23 69 · 7% ∞⌂ (56.7, 80.1) 39/56 11.33 (2.85, 45.1) 0.47¤ðÞ (0.33, 0.67)
Xpert MTB/RIF followed by IFN-γ
if MTB/RIF-negative
92.5%$€ (80.2, 97.5) 37/40 93.8% (83.2, 97.9) 45/48 92.5% (80.2, 97.5) 37/40 93.8%●⌂ (83.2, 97.9) 45/48 14.80 (4.93, 44.43) 0.08§Þ (0.03, 0.24)
Xpert MTB/RIF followed by ADA
(clinical cut-point) if MTB/RIF-negative
81.6%£¥ (66.6, 90.8) 31/38 92.7% (80.6, 97.5) 38/41 91.2% (77.1, 97) 31/34 84.5%▪ (71.3, 92.3) 38/45 11.15 (3.70, 33.49) 0.20¿ (0.10, 0.39)
p-value *; #; $ and £: p < 0.0001 O; □; ×; €
and ¥: p < 0.05
† and ●: P < 0.0001 ◊; ∞; ▪
and ⌂: p < 0.05
¢; º; ¤; §; ¿; ð and Þ:
non overlapping CI
A positive MTB (Mycobacterium tuberculosis) fluid culture and/or positive MTB biopsy culture and/or histology in keeping with MTB infection used as a reference. PPV: positive predictive value, NPV: negative predictive
value, +LR: positive likelihood ratio, -LR: negative likelihood ratio, CI: confidence interval, IFN-γ: interferon gamma, ADA: adenosine deaminase. IFN- γ cut point of 107.7 pg/ml determined by ROC. ADA clinical cut point
of 30 U/L is used for clinical decision-making at Groote Schuur hospital. Rule-in ADA cut point of 48.85U/l determined by ROC.





















Table 3 Per patient diagnostic accuracy of Xpert MTB/RIF assay using centrifuged and uncentrifuged pleural fluid to
diagnose pleural tuberculosis
Assay Definite-TB vs. Non-TB
Sensitivity% (95% CI) Specificity% (95% CI) PPV% (95% CI) NPV% (95% CI)
Pleural fluid (uncentrifuged) 22.5% (12.4, 37.6) 9/40 98% (89.2, 99.7) 48/48 90% (59.6, 98.3) 9/10 60.3% (49.2, 70.4) 48/78
Centrifuged pellet 23.7% (13.0, 39.3) 9/38 100% (91.7, 100) 42/42 100% (70.1, 100) 9/9 59.2% (48.2, 70.3) 42/71
p-value ns* ns* ns* ns*
A median volume of 20 ml of pleural fluid was centrifuged at 3000 × g for 15 min with the pellet resuspended in sterile PBS, followed by Xpert MTB/RIF. A positive
MTB (Mycobacterium tuberculosis) fluid culture and/or positive MTB biopsy culture and/or histology in keeping with MTB infection used as a reference. PPV:
positive predictive value, NPV: negative predictive value, CI: confidence interval, *: Chi squared.
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machine when solid material is used. However this may
not have improved the diagnostic accuracy, in a recent
study, Xpert was unable to detect any TB cases and
more indeterminate results occurred when performed
on finely ground pleural tissue [17].Figure 4 The determination of the: a) limit of detection of
Xpert MTB/RIF and b) analysis of possible inhibition of Xpert
MTB/RIF internal probe in pleural fluid samples. a) To determine
the limit of detection, known amounts of colony forming units of
stock H37Rv were added to 1 ml aliquots of pleural fluid in
duplicate for two repeat experiments. b) CT values for Xpert MTB/RIF
internal probe are represented as box and whiskers (min and max)
for pleural fluid, concentrated pleural fluid (20 ml pellet resuspended
in 1 ml) and sputum. *: p < 0.0001 (Mann-Whitney).Affordability and cost effectiveness remains an import-
ant consideration in resource poor TB endemic coun-
tries. A comprehensive cost effectiveness analysis was
beyond the scope of this paper, and we were unable to
perform a simple cost analysis given the lack of a clinic-
ally validated commercially available unstimulated inter-
feron gamma assay. Although the GeneXpert MTB/RIF
assay is now being rolled out in many TB endemic coun-
tries [28], as we have demonstrated, sensitivity is largely
sub-optimal [6,29]. Although ADA is widely available,
specificity may also be also sub-optimal, as we and
others have previously demonstrated. Nevertheless, it
remains a widely available relatively low cost test. Diag-
nosing drug-resistant pleural TB also merits cost consid-
eration. However, the GeneXpert MTB/RIF assay has a
poor sensitivity in this context and thus whatever diag-
nostic modality is used (unstimulated interferon gamma,
ADA, or GeneXpert MTB/RIF) pleural tissue or fluid
culture is still required for susceptibility testing. There is
an urgent need to make available a commercially and
clinically validated, relatively rapid, single patient use
assay for the measurement of unstimulated interferon
gamma levels in pleural fluid and other forms of EPTB.
There are several limitations of our study. There were
a low proportion of HIV-infected patients and several
patients with unknown HIV status. However, HIV preva-
lence rates in TB patients in the Western Cape Province
of SA are known to be lower than in the rest of the
country [30], and patients often refuse testing. We only
centrifuged 20 ml of fluid. However, we were limited by
available sample, particularly when effusions were locu-
lated. Moreover, a recent paper has showed that increas-
ing the pleural fluid volume to 100 ml does not improve
culture yields, despite improving the time to positivity
[21]. The conclusions drawn here apply to high TB and
HIV burden settings and, for the sake of external valid-
ity, require confirmation in other settings. However,
given that HIV increases the concentration of organisms
in pleural fluid and that the upper limit of the Xpert
sensitivity (95% CI) was 37% suggests that Xpert is un-
likely to perform well in any setting when using pleural
fluid. We did not evaluate the potential impact on
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Xpert compared to empiric treatment based on labora-
tory analysis alone (lymphocyte predominance), however,
this would have require a randomized design and up to
~25% of TB effusions are known to be neutrophil pre-
dominant [23]. The confidence intervals of the sensitiv-
ity estimates for interferon gamma and the GeneXpert
MTB/ RIF assay are not ideal and therefore our findings
should be confirmed using larger sample numbers and
from different parts of the world.
Conclusion
The clinical usefulness of Xpert-MTB/RIF to diagnose
pleural TB is limited by its poor sensitivity. By contrast,
IFN-γ is an excellent rule-in test and, compared to
ADA, has significantly better sensitivity and rule-out
value in a high HIV prevalence setting. The high NPV of
IFN-γ, compared to ADA, is particularly useful to clini-
cians as it prompts further work-up and tissue biopsy in
patients who are unlikely to have TB, however further
prospective testing is required.
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